Actinium Pharmaceuticals Inc

ASE:ATNM   3:59:51 PM EDT
7.91
+0.17 (+2.20%)
Regulatory, Earnings Announcements

Actinium Announces Positive Interim Results From Iomab-B Pivotal Phase 3 Sierra Trial At 75% Of Total Patient Enrollment

Published: 12/07/2020 13:56 GMT
Actinium Pharmaceuticals Inc (ATNM) - Actinium Announces Positive Interim Results From Iomab-b Pivotal Phase 3 Sierra Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting.
Actinium - 100% (49/49) of Patients Receiving a Therapeutic Dose of Iomab-b in Sierra Have Successfully Proceeded to Bone Marrow Transplant.
Actinium Pharmaceuticals Inc - in Total, 78% (88/113) of Patients Enrolled on Sierra Trial Were Able to Receive a Bmt.
Revenue is expected to be $0.07 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $0.07 Million
Next Quarter EPS Guidance is expected to be -$0.29

More details on our Analysts Page.